Cited by 281Nosocomial Infections in ICUAntibiotic Resistance in BacteriaAntifungal resistance and susceptibility

Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management

Barbier, François, Andremont, Antoine, Wolff, Michel, Bouadma, Lila·2013·Current Opinion in Pulmonary Medicine

Abstract

PURPOSE OF REVIEW: The recent evidence is reviewed on clinical epidemiology, trends in bacterial resistance, diagnostic tools and therapeutic options in hospital-acquired pneumonia (HAP), with a special focus on ventilator-associated pneumonia (VAP). RECENT FINDINGS: The current incidence of VAP ranges from two to 16 episodes for 1000 ventilator-days, with an attributable mortality of 3-17%. Staphylococcus aureus (with 50-80% of methicillin-resistant strains), Pseudomonas aeruginosa and Enterobacteriaceae represent the most frequent pathogens in HAP/VAP. The prevalence of carbapenemase-producing Gram-negative bacilli (GNB) and the emergence of colistin resistance are alarming. Procalcitonin seems to have a good value to monitor the response to treatment. Rapid molecular tests for the optimization of empirical therapy will be available soon. Recent studies support the use of a high-dosing regimen of colistin in HAP/VAP caused by extensively drug-resistant GNB. Linezolid may probably be preferred to vancomycin for a subset of methicillin-resistant S. aureus HAP/VAP. Given the scarcity of novel antimicrobial drugs, different approaches such as bacteriophage therapy or immunotherapy warrant further clinical evaluations. SUMMARY: HAP/VAP is a major cause of deaths, morbidity and resources utilization, notably in patients with severe underlying conditions. The development of new diagnostic tools and therapeutic weapons is urgently needed to face the epidemic of multidrug-resistant pathogens.

Integrity signals

Registry

Crossref · 10.1097/mcp.0b013e32835f27be

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ventilator-associated pneumonia (VAP) frequently occurs in patients requiring mechanical ventilation, leading to high mortality, with an incidence from 5% to 67% depending on the population studied and the diagnostic criteria used.

    “Ventilator-associated pneumonia (VAP) frequently occurs in patients requiring mechanical ventilation, leading to high mortality, with an incidence from 5% to 67% depending on the population studied and the diagnostic criteria used (Barbier et al., 2013; Torres et al., 2017).”

    From Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection (2020) · cites this paper as Barbier et al., 2013

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Barbier, F., Andremont, A., Wolff, M., & Bouadma, L.
Affiliations
  • Centre hospitalier universitaire d'Orléans (FR)
  • Sorbonne Paris Cité (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Bouadma, Lila
Venue
Current Opinion in Pulmonary Medicine
Published
2013-05
Volume
19
Issue
3
Pages
216-228
ISSN
1070-5287 (ISSN-L)
OpenAlex
W2023057700
Cited by
281
References
151
Citations by year
2026: 7 · 2025: 20 · 2024: 15 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 32 · 2019: 20 · 2018: 20 · 2017: 23 · 2016: 21 · 2015: 25 · 2014: 20 · 2013: 5
FWCI
2.61
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Pulmonary Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Astellas Pharma
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Keywords
nosocomial pneumonia, ventilator-associated pneumonia, antimicrobial resistance, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacteriaceae, colistin resistance, procalcitonin, rapid molecular diagnostics, empirical antibiotic therapy, linezolid, vancomycin, phage therapy, immunotherapy, multidrug-resistant pathogens
MeSH terms
Anti-Bacterial Agents, Cross Infection, Humans, Intensive Care Units, Pneumonia, Staphylococcal Infections, Incidence, Prevalence, Cost of Illness, Drug Resistance, Multiple, Bacterial, Pneumonia, Ventilator-Associated, Methicillin-Resistant Staphylococcus aureus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review